A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines



Status:Completed
Conditions:Migraine Headaches
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 65
Updated:5/27/2013
Start Date:November 2012
End Date:March 2013
Contact:Allergan Inc.
Email:clinicaltrials@allergan.com

Use our guide to learn which trials are right for you!


This study will evaluate the effectiveness of OnabotulinumtoxinA to prevent headaches in
patients with Chronic Migraine.


Inclusion Criteria:

- History of chronic migraines

- 15 or more headache days over a 30 day period

- A minimum of 2 consecutive treatment cycles of 100 units onabotulinumtoxinA and a
minimum of 2 consecutive treatment cycles with the onabotulinumtoxinA dosing between
155 and 195 units

Exclusion Criteria:

- Any treatment cycle dose of onabotulinumtoxinA greater than 200 units
We found this trial at
1
site
?
mi
from
New York, NY
Click here to add this to my saved trials